Galimedix Therapeutics

Galimedix Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapies for neurodegenerative diseases. Their lead candidate, GAL-101, is in Phase 2 clinical testing for dry age-related macular degeneration (AMD), glaucoma, and Alzheimer's disease, aiming to block a key step in the neurodegenerative process with a well-tolerated compound. These therapies are designed for convenient administration as eye drops or oral tablets, serving patients and caregivers with a focus on improved tolerability.